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Abstract
Background: In spite of enhanced control efforts, malaria remains a major public health problem causing close to
a million deaths annually. With support from several donors, large amounts of artemisinin-based combination
therapy (ACT) are being deployed in endemic countries raising safety concerns as little is known about the use of
ACT in several of the settings where they are deployed. This project was undertaken to profile the provenance of
the pharmacovigilance reporting of all anti-malarials, including ACT to the WHO adverse drug reaction (ADR)
database (Vigibase™) over the past 40 years.
Methods: The WHO Programme for International Drug Monitoring, the Uppsala Monitoring Centre (UMC) provided
anonymized extracts of Vigibase™ covering the period 1968-2008. All countries in the programme were clustered
according to their malaria control phase and income status. The number of individual case safety reports (ICSRs) of
anti-malarials was analyzed according to those clusters.
Results: From 1968 to 2008, 21,312 ICSRs suspecting anti-malarials were received from 64 countries. Low-income
countries, that are also malaria-endemic (categorized as priority 1 countries) submitted only 1.2% of the ICSRs. Only
60 out of 21,312 ICSRs were related to ACT, 51 of which were coming from four sub-Saharan African countries.
Although very few ICSRs involved artemisinin-based compounds, many of the adverse events reported were
potentially serious.
Conclusions: This paper illustrates the low reporting of ADRs to anti-malarials in general and ACT in particular.
Most reports were submitted by non-endemic and/or high-income countries. Given the current mix of large
donor funding, the insufficient information on safety of these drugs, increasing availability of ACT and
artemisinin-based monotherapies in public and private sector channels, associated potential for inappropriate
use and finally a pipeline of more than 10 new novel anti-malarials in various stages of development, the
presence of well functioning national pharmacovigilance systems is vital to ensure safe and responsible scale
up of ACT deployment. Bringing together the competencies of national pharmacovigilance centres and
various types of organizations in the NGO, academic and private sectors with global coordination to create
short- and long-term solutions may help address the lag between rapidly growing ACT use and poor ADR
reporting.
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In spite of enhanced control efforts, malaria continues
to be a major public health problem in 108 countries
mostly in Africa and parts of Asia. In 2008, approxi-
mately 243 million people fell sick with malaria, with a
majority of cases in the African region (85%), causing
the death of nearly one million people, 85% of whom
were children under five years of age [1]. Malaria and
poverty are connected. In the countries where malaria is
impacting on public health, it is also severely hampering
economic development [2]. As a consequence of
increasing resistance of the malaria parasite to pre-
viously effective monotherapies including chloroquine
(CQ) and sulphadoxine-pyrimethamine (SP), the World
Health Organization (WHO) held a technical consulta-
tion in 2001 endorsing the potential of artemisinin-
based combination therapy (ACT) for drug-resistant
malaria [3]. By 2009, most malaria-endemic countries
had introduced ACT in their national drug policy, as
first-line treatment for uncomplicated Plasmodium falci-
parum malaria [1]. In addition to the ACT, there is a
pipeline of more than 10 new anti-malarials in various
stages of development which will bring several new ther-
apeutic options to the market in the coming decade [4].
Malaria control programmes are being scaled up with
large amounts of international funding commitments
that have increased from US$ 0.3 billion in 2003 to US$
1.7 billion in 2009 thanks to agencies like the Global
Fund to fight AIDS, Tuberculosis and Malaria (Global
Fund), the US President’s Malaria Initiative and the
World Bank, as well as with domestic resources. This
has allowed increased availability of ACT for public sec-
tor use amounting an estimated 240 million ACT dis-
tributed from 2004 to 2008 by national programmes [1].
In addition to the public sector channels, ACT and arte-
misinin-based monotherapies are also available through
formal private health channels and also through infor-
mal outlets where spurious and substandard drugs are
m o r el i k e l yt ob ef o u n d .D u et ot h eh i g hc o s to fA C T
and in a bid to increase access to these medicines, espe-
cially for the poor and vulnerable, the Affordable Medi-
cines Facility - malaria (AMFm) of the Global Fund and
other partners have mobilized huge financial resources
to co-pay the ACT ordered by public and private whole-
salers so that these drugs can be made available at
prices similar to those of CQ and SP [5,6]. The utiliza-
tion of anti-malarial treatments in poor and vulnerable
populations is common. A large amount of these
patients use these drugs in an unsupervised manner
which may lead to a significant number of incorrectly
treated cases [7-9]. An inappropriate treatment, incor-
rect dosing, drug-drug interaction, administration in
populations suffering from or being treated against con-
comitant diseases like HIV/AIDS, tuberculosis,
malnutrition and anaemia can all impact negatively on
drug safety and efficacy [8,10].
A tt h ed a w no fg l o b a lp o l i c yc h a n g et oA C Ti ne a r l y
2000s, safety experience was limited and was mainly
derived from clinical research information from South
East Asia [11]. In general, safety information can be col-
lected through two main pharmacovigilance channels:
(1) spontaneous reporting and (2) systems using phar-
macoepidemiological methods through phase IV clinical
trials or cohorts [8,12]. While spontaneous reporting is
essential for signal detection of rare events, the phar-
maco-epidemiological methods provide additional infor-
mation on both, the utilization and the extent of
consumption, that will permit the determination of fre-
quency of adverse drug reaction (ADR) in the studied
population or the safety comparison between two or
more products [12]. Although ACT are generally con-
sidered safe, there is still little structured information
about their use in real-life settings and the published
data are mainly from clinical trials [13]. Lack of
resources, infrastructure and expertise are the main rea-
sons for the slow development of pharmacovigilance
systems in developing countries, particularly in sub-
Saharan Africa [10,14].
At the global level, the WHO Collaborating Centre
for International Drug Monitoring, the Uppsala Moni-
toring Centre (UMC), collates ADRs via national phar-
macovigilance centres of 104 member countries and 32
associate members (December 2010, see Figure 1) [15].
Since the 2000s, WHO and partners have issued a call
to establish robust pharmacovigilance systems entailing
detection, assessment and prevention of adverse events
associated with the use of medicines distributed
through the public health system and issued guidelines
promoting the development of pharmacovigilance and
post-marketing surveillance in 2006 [16]. In that con-
text, the Roll Back Malaria partnership (RBM) sug-
gested that the introduction of ACT could offer an
opportunity for African countries to put drug safety
monitoring systems in place that could later be
extended to a wide range of medicines [17]. Later,
RBM issued guidelines to include pharmacovigilance
aspects in the Global Fund’sR o u n d8p r o p o s a l sa n d
any other donors supporting procurement and use of
ACT [18,19]. However, despite all those actions imple-
mented since 2000, a recent publication highlighted
the lack of consistent inclusion of pharmacovigilance
activities in proposals and in country plan components
as well as the lack of money requested for such activ-
ities in regard to rapid deployment of anti-malarial
treatment [20]. It can therefore be expected that spon-
taneous ADR reporting for anti-malarials is low, espe-
cially when focusing to the reports coming from
developing and/or endemic countries.
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Page 2 of 10The main objective of the present work was to con-
duct an analysis of 40 years of ADR reporting of anti-
malarials, and to obtain a clear picture on the prove-
nance of the global spontaneous pharmacovigilance data
for anti-malarials as well as the identification of the sus-
pected drugs.
Methods
Provenance and definition of the dataset
The Uppsala Monitoring Centre (UMC) provided an
extract of 40 years Vigibase™ data in the form of a
Microsoft
® Excel file containing anonymized data on
individual case safety reports (ICSR) for all anti-malarial
drugs reported to the WHO database since its inception
in 1968.
UMC programmed the query that extracted all pro-
ducts which were (1) classified in the ATC system as
anti-malarials and (2) considered by the national phar-
macovigilance centre submitting the report as suspected
or interacting with another drug to cause the ADR.
Anti-malarial drugs reported as concomitant medica-
tions were not included in the query. The following
variables were considered for the present publication:
(1) drug name by generic level, (2) report identification
number, (3) year of reporting, (4) country issuing the
report and (5) system-organ class of reaction reported.
Data analysis and statistical method
In order to obtain a better understanding of the prove-
nance of the ADR reports, the different countries were
Year 2000 Year 1992
Year 2005 Year 2010
Figure 1 African WHO members of the programme for international drug monitoring between 1992 and 2010.
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Page 3 of 10clustered according to: (1) their malaria control phase
(control, pre-elimination, elimination, prevention of
reintroduction or certified malaria free) [1] and (2) their
income characteristics as defined by the World Bank
(low, middle or high income) [21]. This allowed the
classification of the countries into three priority groups
according to the matrix presented in Table 1.
The suspected therapies were clustered into three
therapeutic groups: (1) Therapy without artemisinin
derivatives (WAD), (2) Artemisinin-based monotherapy
(AMT) and (3) Artemisinin-based combination therapy
( A C T ) .T h ed a t aw e r ei m p o r t e di n t oaM i c r o s o f t
®
Access (2002) database and then extracted with Micro-
soft
® Excel pivot tables (2002). The results are presented
as the number of data entries per subgroup (n), the total
number of data entries (N) and their frequency
expressed as percentage (P % = n/N × 100). The statisti-
cal evaluation is descriptive only.
Results
General findings
64 countries transmitted 21,312 individual case safety
reports (ICSR) to UMC from 1968 to 2008, which
included a total of 25,247 suspected anti-malarial thera-
pies with a total of 64,243 suspected ADRs to anti-
malarials (Figure 2). A mean of three ADRs were
described per ICSR. 2,781 ICSRs reported more than
one anti-malarial evaluated by the national centre as
suspected or interacting in causing the ADR. A mean of
2.4 anti-malarials were incriminated in this subset of
ICSRs. 2,027 of those reports contained at least one
artemisinin derivative and 1,992 were transmitted by
Thailand in the mid-1990s.
Timeline of reporting
Figure 3 shows the number of ICSRs suspecting anti-
malarials transmitted to UMC over time. The first
report was received in 1968 and the overall total of
ICSRs increased steadily during the 1980s and 1990s
and peaked in 1997.
A mean value of 520 ICSRs suspecting anti-malarials
were submitted per year to UMC between 1968 and
2008.
Provenance of the reports
By end 2008, 91 countries were member countries of
the UMC and 12 of them were located in sub-Saharan
Africa [15]. Approximately 2/3 of the countries world-
wide and 1/2 of the countries located in sub-Saharan
Africa participating in the UMC programme submitted
at least one ICSR suspecting anti-malarials (Table 2).
T a b l e3d e s c r i b e st h en u m b e r sa n dp e r c e n t a g e so f
ICSRs suspecting anti-malarials submitted to UMC
clustered according to the three country priority
groups: high (priority 1), medium (priority 2) and low
( p r i o r i t y3 ) .T h er e p o r t i n grates per million of inhabi-
tants and per thousand of malaria cases are also shown
herein.
T h ef i n d i n g si n d i c a t et h a t8 9 %o fr e p o r t sw e r es u b -
mitted by 10, and 97% of reports were submitted by 20
countries, respectively. Only three countries that are in
the malaria control phase, Thailand, Ghana and South
Africa, rank in the top 20 countries submitting ICSRs
involving anti-malarials. Another analysis indicates that
sub-Saharan Africa, where 586 million people live in
high risk areas and which contributes to 86% of esti-
mated malaria cases and 91% of estimated malaria
deaths [22], submitted less than 2% of all ICSRs invol-
ving anti-malarials. There were also practically no
reports coming from sub-Saharan African countries dur-
ing 1990s and up to early 2000s until reporting slightly
increased. It must be pointed out, however, that during
this period, there were just 3 countries from sub-
Saharan Africa (South Africa, Tanzania, Zimbabwe)
participating in the WHO Programme.
Table 1 Classification of reporting countries into priority
groups
Malaria control phase [1]/
Income [21]
Low
income
Middle
income
High
income
Control Priority 1 Priority 2 Priority 3
Pre-elimination/elimination Priority 2 Priority 2 Priority 3
Prevention of reintroduction/
Malaria free
Priority 3 Priority 3 Priority 3
Individual Case Safety Report (ICSR)
……………………………………………
……………………………
………………………………….
Suspected Adverse Drug Reactions (ADRs):
- …………………….. 
- ……………………..
- ……………………..
Suspected drugs:
- ……………………..
- ……………………..
……………………………………..
…………………………..
……………………………………………….
21,312 ICSRs suspecting anti-malarials reported
64,243 
suspected 
ADRs to anti-
malarials
25,247 
suspected anti-
malarials
Figure 2 Individual Case Safety Reports (ICSR) suspecting anti-
malarials submitted to UMC from 1968 to 2008.
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Page 4 of 10Suspected anti-malarial therapies reported to UMC
Figure 4 presents the number of suspected (or interact-
ing) anti-malarials, which were reported to WHO-UMC,
classified according to their therapeutic group. With a
total of 25,247 suspected anti-malarial treatments, the
majority of the suspected therapies reported were non-
artemisinin compounds (92%) and the minority were
ACT (0.2%). Mefloquine was the most reported drug
with 79% of mefloquine reports coming from priority 3
countries. Of the AMT reported, Thailand reported 96%
of them but, interestingly, did not submit any ICSR sus-
pecting ACT.
The reporting timelines of suspected ACT to UMC
are shown in Figure 5. No report suspecting ACT was
sent before the WHO recommendation of 2001. The
number and percentages of suspected ACT reported to
UMC according to the country priority group are listed
in Table 4. A total of nine countries transmitted a total
of 60 ICSRs suspecting ACT to UMC. From those nine
countries, four are still in the malaria control phase and
are located in sub-Saharan Africa (Ghana, Nigeria,
Tanzania and South Africa) whilst the others are non-
endemic (France, Germany, the Netherlands, Switzerland
and the United States).
ADRs reported for artemisinin-based compounds,
administered either as monotherapy or combination
therapy, affected the following 5 most frequently
reported MedDRA System Organ Classes: nervous
system disorders, gastrointestinal disorders, psychiatric
disorders, metabolism and nutrition disorders and car-
diac disorders.
Discussion
This publication explores the scope and scale of spon-
taneous ADR reporting for anti-malarials and particu-
larly ACT until 2008, with the aim to evaluate and
measure the past and current activities in pharmacov-
igilance for anti-malarials around the world. This work
has been accomplished using the largest global data-
base, Vigibase™ of the WHO Programme for Interna-
tional Drug Monitoring maintained by the UMC in
Sweden. An extensive description of the nature of the
ADRs in relation to the suspected drugs that were
reported is planned to be the objective of another
publication.
All products that were classified in the ATC system as
anti-malarials and considered as suspected or interacting
in causing the ADR were extracted from Vigibase™ and
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Figure 3 Number of Individual Case Safety Reports (ICSR) suspecting anti-malarials transmitted to UMC per year (1968 - 2008). Note:
21,312 ICSRs have been submitted from 1968 to 2008; in 1997, 1458 of the 2289 reports have been submitted by Thailand; in 2004, 1464 of the
2025 reports have been submitted by the Netherlands.
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Page 5 of 10Table 2 List and characteristics of the reporting countries participating to the WHO-UMC programme in 2008 (in
brackets: year of entry in the WHO-UMC programme)
Malaria control
phase [1]/Income
[21]
Low income Middle income High income
Control Priority 1: Priority 2:
Ghana (2001) Brazil (2001)
Mozambique (2005) China (1998)
Tanzania (1993) Colombia (2004)
Vietnam (1999) Costa Rica (1991)
Zimbabwe (1998) India (1998)
Indonesia (1990)
& 5 countries participating to the UMC
programme did not submit any report.
Nigeria (2004)
Peru (2002)
Philippines (1995)
South Africa (1992)
Suriname (2007)
Thailand (1984)
Venezuela (1995)
& 3 countries participating to the UMC
programme did not submit any report
Pre-elimination/
elimination
2 countries participating to the UMC
programme did not submit any report.
Priority 2: 1 country participating to the UMC
programme did not submit any report.
Argentina (1994)
Iran (1998)
Malaysia (1990)
Mexico (1999)
Turkey (1998)
& 1 country participating to the UMC
programme did not submit any report.
Prevention of
reintroduction/
Malaria free
Priority 3: Priority 3:
Bulgaria (1975) Australia (1968)
Chile (1996) Austria (1991)
Cuba (1994) Belgium (1977)
Lithuania (2005) Canada (1968)
Macedonia (2000) Croatia 1992)
Morocco (1992) Cyprus (2001)
Poland (1972) Czech Republic (1992)
Romania (1976) Denmark (1971)
Tunisia (1993) Finland (1974)
Uruguay (2001) France (1976)
Former SFR Yugoslavia Germany (1968)
Greece (1990)
& 11 countries participating to the UMC
programme did not submit any report.
Hungary (1990)
Iceland (1990)
Ireland (1968)
Israel (1973)
Italy (1975)
Japan (1972)
Netherlands (1968)
New Zealand (1968)
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Page 6 of 10included in the present analysis. The assessment of
causality between the anti-malarial and the ADR as well
as the exact treatment indication, were not included in
the query because this information is often incompletely
transmitted to UMC. Therefore, drugs that are not clas-
sified as anti-malarials in the ATC system but can be
used as anti-malarials, like doxycycline, have not been
included in the analysis. Conversely, anti-malarials that
might have been used for other indications have been
included in the present analysis.
Globally, the submission rates of ICSRs suspecting
anti-malarials increased until reaching a maximum in
1997 and currently seem to remain stable. The majority
of those ICSRs were from priority 3 countries (high
income and non-endemic) since the inception of the
WHO database in 1968. This trend showing that high
income and non-endemic countries are reporting more
often has remained stable over the last decade with six
to 40 times more ICSRs per inhabitant submitted by
high income and non-endemic countries (priority 3)
than by endemic and poorer countries (priority 1 and
2). The ICSRs submitted since the year 2000 per malaria
case show also that the priority 1 countries, mainly
located in sub-Saharan Africa, seem to submit less
ICSRs than priority 2 countries. Assuming that patients
in high income and/or non-endemic countries are
usually taking anti-malarials for travel purposes, the data
extracted from the Vigibase™ is probably reflecting the
safety of anti-malarials taken as prophylactic rather than
as curative treatments. This assumption may be sup-
ported by the finding that mefloquine is the most fre-
quently reported anti-malarial and that this compound
was extensively used over the years in Northern hemi-
sphere countries for malaria prophylaxis.
Even though ACT is nowadays widely distributed in
endemic countries, only 60 ICSRs suspecting ACT have
ever been submitted by nine countries (four of them
located in sub-Saharan Africa). Those reports were all
sent after the WHO recommendation to use ACT for
uncomplicated malaria was published in 2001 [3].
Nevertheless, it might actual l yb et h a tm o r eI C S R ss u s -
pecting ACT have been submitted in the mid-1990s. It
is unfortunately not possible to know if the 2,027 arte-
misinin derivatives reported on the same ICSR with
other anti-malarials were administered simultaneously as
one ACT or separately as one artemisinin-based mono-
therapy and one non-artemisinin therapy (but within a
timeframe allowing the suspicion of both or more
Table 2 List and characteristics of the reporting countries participating to the WHO-UMC programme in 2008 (in
brackets: year of entry in the WHO-UMC programme) (Continued)
Norway (1971)
Oman (1995)
Portugal (1993)
Singapore (1993)
Slovakia (1993)
Spain (1984)
Sweden (1968)
Switzerland (1991)
United Kingdom (1968)
United States (1968)
& 5 countries participating to the UMC
programme did not submit any report.
Table 3 Numbers, percentages and reporting rates of Individual Case Safety Reports (ICSR) suspecting anti-malarials
submitted to WHO-UMC, clustered according to the country priority groups
Priority 1 countries Priority 2 countries Priority 3 countries All reporting countries
Number of ICSRs submitted 255 2,983 18,074 21,312
% of total reports 1.2% 14.0% 84.8% 100%
Number of ICSRs (2000-2008) 247 686 8,149 9,082
% of total reports (2000-2008) 2.7% 7.6% 89.7% 100%
Population in thousand (2009) [27] 191,062 3,766,911 1,098,359 5,056,332
Number of ICSRs (2000-2008)/Million population 1.3 0.2 7.4 1.8
Malaria cases in thousand [1] 4,109 3,943 0.2
1 8,052
Number of ICSRs (2000-2008)/thousand malaria case 0.06 0.17 38,439 1.1
1 Malaria cases have been reported by Morocco (118 cases) and Oman (94 cases) [1].
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Page 7 of 10drugs). Many of the adverse events reported for ACT or
artemisinin-based monotherapy could be potentially ser-
ious and involved cardiac, gastro-intestinal, nervous and
psychiatric system. At this stage those results should be
interpreted cautiously because they may reflect either
the ADR profile of artemisinin, the drugs given conco-
mitantly to artemisinin or a combination of both.
The inverse relationship between the huge utilization of
anti-malarials and the very low submission rate of ICSRs
by priority 1 countries to the WHO drug safety database is
coinciding with the fact that sub-Saharan African coun-
tries are relatively absent from and/or only recently parti-
cipating in the WHO Programme for International Drug
Monitoring (see Figure 1) [15]. The unacceptably low pre-
sence and functioning of national pharmacovigilance sys-
tems in sub-Saharan Africa may be due, in addition to
lack of human resources, infrastructure and competing
p r i o r i t i e s ,t ot h ea b s e n c eo f earmarked funds and clear
guidelines from donor agencies, issues which have been
highlighted in a recent publication that examined the sta-
tus of pharmacovigilance for anti-malarials [20].
The WHO and various donor agencies are currently
advocating the development of pharmacovigilance sys-
tems in countries where drugs are extensively distribu-
ted through public health channels [16,17]. After RBM’s
call to include pharmacovigilance activities in Global
Fund applications followed by further calls from the
Global Fund in 2010 for stringent safety monitoring of
products, the inclusion of pharmacovigilance as a speci-
fic component of the 10
th round of the Global Fund,
should drive development in a positive direction
[18,19,23]. This is important and requires support from
all stakeholders to ensure that the safety of ACT as illu-
strated in the WHO’sV i g i b a s e ™ is reflective of the
countries consuming ACT. Strengthening of sponta-
neous reporting along with pharmaco-epidemiological
methods should provide the needed safety information
on ACT, for the benefit of both malaria-endemic coun-
tries and the global medical community as a whole. The
creation of an office in Africa (Accra, Ghana) by the
UMC and the establishment of the University of Ghana
22
38
1
27
2061
1
1
2
2
3
6
7
8
12
13
16
35
128
167
265
278
757
798
937
978
1335
2316
2743
2748
0 1000 2000 3000 4000
artemether/lumefantrine
amodiaquine/artesunate
dihydroartemisinin
artemether
artesunate
tafenoquine
cinchona spp. Bark
lumefantrine
chlorproguanil
primaquine/quinine
chloroquine/primaquine
chloroquine/mepacrine/hydroxychloroquine
pyrimethamine/chloroquine
chloroquine/mepacrine
pyrimethamine/sulfamide/mefloquine
cycloguanil
dapsone/chlorproguanil
halofantrine
amodiaquine
chloroquine/proguanil
pyrimethamine/dapsone
pyrimethamine
pyrimethamine/sulfamide
proguanil
proguanil/atovaquone
primaquine
quinine derivatives
hydroxychloroquine
chloroquine
mefloquine
Number of suspected anti-malarials
WAD
ACT
AMT
9542
91.5%
8.3%
0.2%
Figure 4 Number of suspected anti-malarial treatments
reported to UMC from 1968 to 2008. (WAD, Therapy without
artemisinin derivatives; AMT, Artemisinin-based monotherapy; ACT,
Artemisinin-based combination therapy). Note: 25,247 suspected
anti-malarials have been reported from 1968 to 2008.
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Figure 5 Number of suspected ACT reported to UMC per year
(2001 - 2008). (ACT, Artemisinin-based combination therapy). Note:
60 suspected ACT have been reported from 2001 to 2008; in 2006,
37 of the 39 suspected ACT have been reported by Ghana).
Table 4 Number and percentages of suspected ACT
reported to UMC clustered according to the country
priority groups from 2001 to 2008
Priority 1
countries
Priority 2
countries
Priority 3
countries
All
reporting
countries
Number of
suspected ACT
40
1 11
2 9
3 60
% of total number
of suspected ACT
67% 18% 15% 100%
Note: ACT, Artemisinin-based combination therapy; SSA, sub-Saharan Africa.
1 Reports have been submitted by Ghana and Tanzania.
2 Reports have been submitted by Nigeria and South Africa.
3 Reports have been submitted by France, Germany, the Netherlands,
Switzerland and United States.
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Page 8 of 10Medical School as a WHO Collaborating Centre for
Advocacy and Training in Pharmacovigilance [24] are
likely to provide rallying points for the mobilization of
technical and financial resources for the expansion of
pharmacovigilance in Africa.
In order to supplement these long-term capacity
building and systems strengthening efforts, the RaPID
initiative (Rapid Pharmacovigilance Implementation in
Development Countries), is working with public health
programs in various countries to provide ‘instant’ solu-
tions through short workshops and electronic-based
support to analyse and submit ICSRs to the WHO data-
base. A WHO-funded study conducted by RaPID high-
lighted that several countries had collected a large
number of ICSR (several hundred), but due to various
reasons, were not able to submit these reports to the
WHO database [25]. The RaPID initiative includes a
consortium of academic, NGO and private sector orga-
nizations from developed and developing countries [26].
Conclusions
This paper shows that there is very low spontaneous
reporting of ADRs to anti-malarials in general and ACT in
particular, considering the scale of use of anti-malarials
globally. Furthermore, the ADR data is being submitted
predominantly from non-endemic and/or high-income
countries. The reporting figures are even more alarming,
when considering that there is practically no reporting of
ACT (only 60 reports until end of 2008) while the national
programmes reported that an estimated 240 million ACT
have been distributed from 2004 to 2008 [1].
It can be inferred that national pharmacovigilance
reporting systems are extremely weak or non-existent in
a large number of malaria-endemic countries, especially
in sub-Saharan Africa. Additional studies will need to be
conducted in order to identify the weak links along the
pharmacovigilance supply chain, which could be one or
more of the following: 1) completion of ICSRs by health
workers, 2) analysis and review of the ICSRs by the phar-
macovigilance department, 3) submission of ICSRs to
UMC, 4) conducting signal detection and strengthening,
5) establishing national policies based on findings and 6)
providing feedback to the health workers. In addition,
health workers should also be appropriately trained in
pharmacovigilance issues and adequate equipment
should be provided to them. A large number of patients
are treated in rural areas and resource limited settings,
such patients will also need to be followed-up in order to
detect ADRs in a comprehensive way.
Given the current mix of large funding from donors,
the availability of ACT and artemisinin-based mono-
therapies in public and private sector channels (includ-
ing informal channels), the significant potential for
inappropriate use and overuse, especially in countries
where ACT are available over-the-counter, the insuffi-
cient information on safety of these drugs in the African
context and finally a pipeline of more than 10 novel
anti-malarials in various stages of development [4], the
presence of active and well functioning national phar-
macovigilance systems is vital to ensure safe and respon-
sible scale up of ACT use.
The recent initiative by the Global Fund and WHO to
develop a joint pharmacovigilance strategy and a recom-
mendation that Global Fund recipient countries have a
minimum capacity of pharmacovigilance systems in
place is highly encouraging [16,23]. Bringing together
the competencies of national pharmacovigilance centres
and organizations in the NGO, academic and private
sector with global coordination to create short- and
long-term solutions is required to address the lag
between rapidly growing ACT use and ensuring public
health safety.
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